Information needs among women taking part in primary HPV screening in England: a content analysis.
Public health
preventive medicine
primary care
qualitative research
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Introducing primary human papillomavirus (HPV) testing to cervical screening programmes means changes to the results women receive. We explored additional information needs among women undergoing HPV primary screening. Women were sent a postal questionnaire shortly after receiving their results and 6 and 12 months later. Each questionnaire asked if women had any unanswered questions about cervical screening or HPV testing. Free-text responses constituted the data. Themes were identified using content analysis. National Health Service (NHS) Cervical Screening Programme, England. 381 women who recorded one or more free-text responses. The most common theme represented women's emotional responses and attempts to understand their results. This theme was raised by 45% of women overall, but was as high as 59% in the HPV cleared group. General questions about the cause and epidemiology of HPV were raised by 38% of women and were more common among those testing HPV positive with normal cytology (52%). Questions about the purpose and procedure for HPV testing were most common among HPV-negative women (40%, compared with 16%-24% of the other results groups). Questions about future implications of test results were raised by 19% of women, and this theme was most common among those with persistent HPV. Despite provision of information alongside screening invitations, women can still have unanswered questions following receipt of their results. Details about the epidemiology of HPV and why cervical screening procedures are changing should be included with screening invitations. Some results groups may benefit from additional tailored information with their results letter.
Identifiants
pubmed: 33323451
pii: bmjopen-2020-044630
doi: 10.1136/bmjopen-2020-044630
pmc: PMC7745520
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e044630Subventions
Organisme : Department of Health
ID : DRF-2017-10-105
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C49896/A17429
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C7492/A17219
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Cancer. 2017 May 15;140(10):2192-2200
pubmed: 28006858
Br J Cancer. 2005 Jan 31;92(2):265-70
pubmed: 15655553
Int J Cancer. 2018 Aug 15;143(4):735-745
pubmed: 29341110
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Vaccine. 2019 Jan 14;37(3):412-416
pubmed: 30551987
Br J Cancer. 2003 Jan 13;88(1):42-6
pubmed: 12556957
J Nutr Educ Behav. 2002 Jul-Aug;34(4):224-30
pubmed: 12217266
Psychooncology. 2018 Jun;27(6):1559-1564
pubmed: 29521462
Int J Cancer. 2019 Jul 1;145(1):29-39
pubmed: 30549273
BMJ. 2019 Feb 6;364:l240
pubmed: 30728133
J Womens Health (Larchmt). 2019 Mar;28(3):384-392
pubmed: 30481121
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv
pubmed: 19891902
BMJ Open. 2016 Dec 23;6(12):e014356
pubmed: 28011816
Int J Cancer. 2020 Apr 15;146(8):2113-2121
pubmed: 31251820
J Natl Cancer Inst. 2011 Mar 2;103(5):368-83
pubmed: 21282563
Public Health Res Pract. 2019 Jul 31;29(2):
pubmed: 31384888
Br J Cancer. 2012 Jul 10;107(2):243-54
pubmed: 22699825
J Fam Plann Reprod Health Care. 2009 Jan;35(1):29-33
pubmed: 19126314